Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of a patient with advanced BRAF-mutant melanoma.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Mar 2014

Ashworth Michelle T, Daud Adil

Abstract excerpt

A 49-year-old man initially diagnosed in 1995 with cutaneous melanoma presented to the authors' institution in 2009 with metastatic, BRAF V600E-mutant melanoma. His treatment course to date has included surgery, adjuvant radiotherapy, and interferon, metastasectomies, granulocyte-macrophage colony-stimulating factors, a clinical trial with the BRAF inhibitor vemurafenib (PLX-4032), clinical trial with combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biopsy
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Staging

Share to Positron-Emission Tomography

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Source

Identifiers

PMID: 24616537
DOI: 10.6004/jnccn.2014.0033

Genes

BRAF
CTLA4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of a patient with advanced BRAF-mutant melanoma.PMID 24616537Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

First line treatment of BRAF mutated advanced melanoma: Does one size fit all?Semantic proximity Read ↗

Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect.Semantic proximity Read ↗

[BRAF mutation: a novel approach in targeted melanoma therapy].Semantic proximity Read ↗

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read ↗

Treating metastatic melanoma in 2014: what just happened and what is next?Semantic proximity Read ↗

Emerging targeted therapies for melanoma.Semantic proximity Read ↗

Advances in the systemic treatment of metastatic melanoma.Semantic proximity Read ↗

What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?Semantic proximity Read ↗

BRAFV600E-mutant melanoma presenting with cardiac involvement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.